Completed PHASE4 INTERVENTIONAL 1-arm NCT01408199

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus (ORDI-02)

Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus

Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Updated 5 times since 2017 Last updated: Aug 2, 2011 Started: Jan 31, 2010 Primary completion: Aug 31, 2010 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01408199, this PHASE4 trial focuses on Cutaneous Lupus and remains completed. Sponsored by Hospital Universitari Vall d'Hebron Research Institute, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Universitari Vall d'Hebron Research Institute

Data source: Hospital Universitari Vall d'Hebron Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain